10 Best Small-Cap Healthcare Stocks To Buy Now

2. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Number of Hedge Fund Holders: 37 

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and inflammatory diseases. At its core, Nurix specializes in protein degradation and modulation technologies, creating small-molecule drugs that can selectively target and eliminate disease-causing proteins.

A significant catalyst for Nurix Therapeutics, Inc. (NASDAQ:NRIX) is its strategic collaborations and promising clinical data. The company has established partnerships with major pharmaceutical companies like Gilead Sciences, Sanofi, and Seagen, which help in co-development and co-commercialization of multiple drug candidates. Additionally, Nurix has reported positive clinical data, such as the promising results from its NX-5948 trial for chronic lymphocytic leukemia, which demonstrated an objective response rate of 69.2%. This clinical success supports the potential best-in-class profile for NX-5948, which could drive future growth and increase earnings. The future growth of Nurix Therapeutics is likely to be driven by its continued success in clinical trials and expansion of its drug pipeline. The company’s focus on developing novel therapies for B-cell malignancies and autoimmune diseases positions it well in a growing market.

As of Q2 2024, around 37 hedge fund holders held stakes in the stock with Redmile Group being the largest stakeholder with 4,423,616 shares worth $92,320,866. The stock has a Strong Buy rating based on 12 Wall Street Analysts. The average price target is $29.00, with forecasts ranging from $15.00 to $36.00, indicating a 15.08% increase from the current price of $25.20.